{"url_path":"/sec/kmts/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1877184/0001193125-26-303397-index.html","accession_number":"0001193125-26-303397","cik":"0001877184","ticker":"KMTS","issuer_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1877184/0001193125-26-303397-index.html","primary_entity_key":"0001877184","primary_entity_name":"KESTRA MEDICAL TECHNOLOGIES, LTD."},"word_count":764,"has_tables":true,"body_markdown":"10-K\n\n0001877184FYfalse00-0000000Yeshttp://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMemberhttp://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMemberoneonehttp://fasb.org/srt/2025#ChiefExecutiveOfficerMember2http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMembertwelve months0001877184us-gaap:AdditionalPaidInCapitalMember2024-05-012025-04-3000018771842024-04-300001877184us-gaap:CommonStockMember2026-04-300001877184us-gaap:ResearchAndDevelopmentExpenseMember2025-05-012026-04-300001877184ck0001877184:CreditAgreementMembersrt:MinimumMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-290001877184ck0001877184:WestAffumHoldingsDesignatedActivityCompanyMemberck0001877184:WestAffumIntermediateHoldingsCorpMemberus-gaap:InvestorMember2025-05-012026-04-300001877184ck0001877184:IndirectlyOwnsMemberus-gaap:IPOMemberck0001877184:KestraMedicalTechnologiesLtdMember2025-03-070001877184ck0001877184:UnvestedMarketBasedRestrictedStockUnitMember2026-04-300001877184us-gaap:EmployeeStockOptionMember2025-05-012026-04-300001877184us-gaap:DomesticCountryMemberck0001877184:Pre-TCJAMember2026-04-300001877184us-gaap:CommonStockMemberus-gaap:IPOMember2025-03-140001877184ck0001877184:CreditAgreementMemberck0001877184:LenderMembersrt:MaximumMemberck0001877184:TermLoan2024Member2023-09-290001877184us-gaap:RedeemablePreferredStockMember2024-04-300001877184us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-05-012025-04-300001877184ck0001877184:CreditAgreementMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2025-05-012026-04-300001877184ck0001877184:MedicalRentalEquipmentMembersrt:MaximumMember2025-04-300001877184us-gaap:WarrantMemberck0001877184:TermLoan2024Member2025-05-012026-04-300001877184ck0001877184:CreditAgreementMemberck0001877184:ThirdTrancheMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-290001877184ck0001877184:FirstTrancheMember2023-09-292023-09-290001877184ck0001877184:FirstDrawMemberck0001877184:TermLoan2024Member2023-09-292023-09-290001877184us-gaap:RedeemablePreferredStockMember2024-07-012024-07-310001877184ck0001877184:MarketBasedRestrictedStockUnitsMember2025-05-012026-04-300001877184us-gaap:RestrictedStockMemberus-gaap:IPOMember2025-05-012026-04-300001877184ck0001877184:CreditAgreementMemberck0001877184:SecondTrancheMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-292023-09-290001877184ck0001877184:IncentiveUnitsMember2024-05-012025-04-300001877184us-gaap:CommonStockMemberus-gaap:IPOMember2025-03-070001877184ck0001877184:LoanAgreementMemberck0001877184:TrancheCLoanMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-102026-07-100001877184us-gaap:DomesticCountryMember2026-04-300001877184us-gaap:CollateralizedCreditCardSecuritiesMember2025-04-300001877184ck0001877184:PerformanceBasedRestrictedStockUnitMember2026-04-300001877184ck0001877184:EmployeeStockPurchasePlanMember2025-05-012026-04-300001877184us-gaap:RestrictedStockMember2024-05-012025-04-300001877184us-gaap:AdditionalPaidInCapitalMember2025-04-300001877184us-gaap:SubsequentEventMember2026-07-102026-07-100001877184us-gaap:WarrantMemberck0001877184:TermLoan2024Member2024-05-012025-04-300001877184ck0001877184:Market-BasedRestrictedStockUnitsMember2025-05-012026-04-300001877184srt:MinimumMemberck0001877184:MedicalRentalEquipmentMember2026-04-300001877184ck0001877184:TestEquipmentMember2026-04-300001877184country:IE2026-04-300001877184us-gaap:RestrictedStockMemberus-gaap:IPOMember2026-04-300001877184ck0001877184:CreditAgreementMembersrt:MinimumMemberck0001877184:FirstTrancheMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-292023-09-290001877184us-gaap:RestrictedStockMember2025-05-012026-04-300001877184srt:MaximumMemberck0001877184:BatteriesMember2026-04-300001877184ck0001877184:WestAffumHoldingsDesignatedActivityCompanyMemberck0001877184:ClassARedeemableOrdinarySharesMemberus-gaap:InvestorMember2024-07-012024-07-310001877184us-gaap:CommonStockMemberck0001877184:WestAffumHoldingsLPMemberus-gaap:IPOMember2025-03-072025-03-070001877184us-gaap:CommonStockMemberck0001877184:PublicUnderwrittenOfferingMember2025-12-040001877184srt:MaximumMember2026-04-300001877184us-gaap:MeasurementInputRiskFreeInterestRateMember2026-04-300001877184ck0001877184:CreditAgreementMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-292023-09-290001877184ck0001877184:Performance-BasedRestrictedStockUnitsMember2025-05-012026-04-3000018771842024-05-012025-04-300001877184srt:MinimumMemberus-gaap:DomesticCountryMember2025-05-012026-04-300001877184ck0001877184:KestraMedicalTechnologiesLtdMember2025-05-012026-04-3000018771842024-07-012024-07-310001877184us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-300001877184ck0001877184:CreditAgreementMemberck0001877184:ThirdTrancheMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-292023-09-2900018771842023-11-012024-04-300001877184us-gaap:EmployeeStockOptionMember2025-05-012026-04-300001877184ck0001877184:MedicalRentalEquipmentMembersrt:MaximumMember2026-04-300001877184ck0001877184:WestAffumIntermediateHoldingsCorpMember2025-05-012026-04-300001877184us-gaap:RetainedEarningsMember2024-04-300001877184us-gaap:AdditionalPaidInCapitalMember2025-05-012026-04-300001877184srt:MinimumMemberck0001877184:MedicalRentalEquipmentMember2025-04-300001877184us-gaap:StateAndLocalJurisdictionMember2026-04-300001877184us-gaap:LeaseholdImprovementsMember2026-04-3000018771842026-02-012026-04-300001877184us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2026-04-300001877184us-gaap:ResearchAndDevelopmentExpenseMember2024-05-012025-04-3000018771842026-07-090001877184ck0001877184:OfficeEquipmentAndFurnitureMember2026-04-300001877184us-gaap:RedeemablePreferredStockMember2024-05-012024-05-310001877184us-gaap:ForeignCountryMember2025-05-012026-04-300001877184ck0001877184:WarrantsToPurchaseCommonSharesMember2025-05-012026-04-300001877184ck0001877184:CostsOfRevenueMemberck0001877184:BatteriesMember2025-05-012026-04-300001877184us-gaap:AdditionalPaidInCapitalMember2026-04-3000018771842025-04-3000018771842025-10-3100018771842024-08-012024-08-310001877184us-gaap:IPOMember2025-03-072025-03-070001877184us-gaap:IPOMember2025-05-012026-04-300001877184ck0001877184:TestEquipmentMember2025-04-300001877184us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-04-300001877184ck0001877184:FourZeroOneKPlanMember2025-05-012026-04-300001877184ck0001877184:IncentiveUnitsMember2025-04-300001877184ck0001877184:TermLoanMember2025-04-300001877184ck0001877184:LoanAgreementMemberck0001877184:LenderMember2026-07-102026-07-100001877184us-gaap:RetainedEarningsMember2025-05-012026-04-300001877184us-gaap:CommonStockMember2025-04-300001877184ck0001877184:TrancheDLoanMemberck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-100001877184us-gaap:NoncontrollingInterestMember2024-05-012025-04-300001877184us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-300001877184us-gaap:MeasurementInputRiskFreeInterestRateMember2025-04-300001877184srt:MinimumMemberck0001877184:BatteriesMember2026-04-300001877184ck0001877184:UnvestedRestrictedUnitsMember2026-04-300001877184us-gaap:CommonStockMemberus-gaap:IPOMemberck0001877184:KestraMedicalTechnologiesLtdMember2025-03-072025-03-070001877184us-gaap:CommonStockMemberus-gaap:IPOMember2025-03-072025-03-070001877184ck0001877184:TermLoan2024Member2025-05-012026-04-300001877184us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2025-05-012026-04-300001877184us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2025-04-300001877184us-gaap:LetterOfCreditMemberus-gaap:LeaseAgreementsMember2026-04-300001877184us-gaap:RestrictedStockMember2022-09-012024-10-160001877184us-gaap:FairValueInputsLevel3Member2025-05-012026-04-300001877184us-gaap:RedeemablePreferredStockMember2023-05-022023-05-020001877184us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-05-012026-04-300001877184ck0001877184:WestAffumHoldingsDesignatedActivityCompanyMemberck0001877184:ClassARedeemableOrdinarySharesMemberus-gaap:InvestorMember2024-07-310001877184us-gaap:RestrictedStockUnitsRSUMember2025-05-012026-04-300001877184us-gaap:StateAndLocalJurisdictionMember2025-05-012026-04-300001877184ck0001877184:ComputerSoftwareAndEquipmentMember2026-04-300001877184us-gaap:CommonStockMember2025-12-042025-12-040001877184us-gaap:AdditionalPaidInCapitalMember2024-04-300001877184ck0001877184:WarrantsToPurchaseCommonSharesMember2024-05-012025-04-3000018771842025-12-310001877184us-gaap:EmployeeStockOptionMember2024-05-012025-04-300001877184ck0001877184:ThirdTrancheMemberck0001877184:TermLoan2024Member2025-05-012026-04-300001877184ck0001877184:IncentiveUnitsMember2024-04-300001877184us-gaap:LeaseholdImprovementsMember2025-04-300001877184us-gaap:MeasurementInputPriceVolatilityMember2025-04-300001877184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-04-300001877184us-gaap:RetainedEarningsMember2026-04-300001877184ck0001877184:UnvestedMarketBasedRestrictedStockUnitMember2025-05-012026-04-300001877184ck0001877184:AvailableForSaleMarketableSecuritiesMember2026-04-300001877184ck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMemberck0001877184:TrancheALoanMember2026-07-102026-07-1000018771842025-05-012026-04-300001877184us-gaap:MeasurementInputSharePriceMember2025-04-300001877184ck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberus-gaap:SecuredOvernightFinancingRateSofrMemberck0001877184:LenderMember2026-07-102026-07-100001877184ck0001877184:CreditAgreementMemberck0001877184:LenderMembersrt:MaximumMemberck0001877184:TermLoan2024Member2023-09-292025-03-310001877184ck0001877184:SecondTrancheAndThirdTrancheMember2024-10-312024-10-310001877184us-gaap:CommonStockMember2024-05-012025-04-300001877184us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-300001877184ck0001877184:RestrictedClassACommonUnitsMemberus-gaap:IPOMember2025-05-012026-04-300001877184ck0001877184:TermLoanMember2026-04-3000018771842023-09-292023-09-290001877184ck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMemberck0001877184:TrancheALoanMember2026-07-100001877184us-gaap:ForeignCountryMember2026-04-300001877184ck0001877184:DirectlyOwnsMemberus-gaap:IPOMemberck0001877184:KestraMedicalTechnologiesLtdMember2025-03-070001877184us-gaap:MeasurementInputExpectedDividendRateMember2025-04-300001877184us-gaap:RestrictedStockMember2026-04-300001877184us-gaap:CommonStockMember2025-05-012026-04-3000018771842026-04-300001877184ck0001877184:LoanAgreementMemberck0001877184:TrancheCLoanMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-100001877184us-gaap:CommonStockMemberck0001877184:PublicUnderwrittenOfferingMember2025-12-042025-12-040001877184us-gaap:WarrantMember2025-09-042025-09-040001877184us-gaap:RetainedEarningsMember2025-04-300001877184ck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMembersrt:MaximumMember2026-07-100001877184us-gaap:RedeemablePreferredStockMember2024-05-012025-04-300001877184us-gaap:RedeemablePreferredStockMember2023-03-312023-03-310001877184us-gaap:RedeemablePreferredStockMemberck0001877184:DirectlyOwnsMemberck0001877184:KestraMedicalTechnologiesLtdMember2026-04-300001877184us-gaap:CommonStockMember2024-04-300001877184ck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-102026-07-100001877184ck0001877184:MedicalRentalEquipmentMember2025-04-300001877184us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-300001877184ck0001877184:PerformanceBasedRestrictedStockUnitMember2025-05-012026-04-300001877184ck0001877184:TrancheBLoanMemberck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-100001877184ck0001877184:ThirdTrancheMemberck0001877184:TermLoan2024Member2025-02-252025-02-250001877184us-gaap:BaseRateMemberck0001877184:LoanAgreementMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-102026-07-100001877184us-gaap:DomesticCountryMemberck0001877184:Post-TCJAMember2026-04-300001877184ck0001877184:ComputerSoftwareAndEquipmentMember2025-04-300001877184us-gaap:RestrictedStockMember2025-04-300001877184us-gaap:LetterOfCreditMemberus-gaap:LeaseAgreementsMember2025-04-300001877184us-gaap:DomesticCountryMembersrt:MaximumMember2025-05-012026-04-300001877184us-gaap:DomesticCountryMember2025-05-012026-04-300001877184us-gaap:CommonStockMemberus-gaap:IPOMembersrt:MaximumMember2026-04-300001877184us-gaap:RedeemablePreferredStockMember2022-05-310001877184ck0001877184:FirstTrancheMember2023-09-290001877184ck0001877184:CreditAgreementMemberck0001877184:SecondTrancheMemberck0001877184:LenderMemberck0001877184:TermLoan2024Member2023-09-290001877184us-gaap:FairValueInputsLevel3Member2026-04-300001877184us-gaap:FairValueInputsLevel2Member2026-04-300001877184us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2026-04-300001877184ck0001877184:IndirectlyOwnsMemberus-gaap:RedeemablePreferredStockMemberck0001877184:KestraMedicalTechnologiesLtdMember2026-04-300001877184us-gaap:FairValueInputsLevel3Member2025-04-300001877184ck0001877184:RestrictedClassACommonUnitsMember2024-07-242024-11-030001877184us-gaap:EmployeeStockMember2025-05-012026-04-300001877184us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-05-012026-04-300001877184ck0001877184:OfficeEquipmentAndFurnitureMember2025-04-300001877184us-gaap:RedeemablePreferredStockMember2025-05-012026-04-300001877184us-gaap:MeasurementInputPriceVolatilityMember2026-04-300001877184srt:MinimumMember2026-04-300001877184us-gaap:RetainedEarningsMember2024-05-012025-04-300001877184us-gaap:ConstructionInProgressMember2026-04-300001877184ck0001877184:UnvestedRestrictedUnitsMember2025-05-012026-04-300001877184ck0001877184:LoanAgreementMembersrt:MinimumMemberus-gaap:SubsequentEventMemberck0001877184:LenderMember2026-07-100001877184srt:MinimumMember2025-05-012026-04-300001877184ck0001877184:WestAffumHoldingsDesignatedActivityCompanyMemberus-gaap:CommonClassAMemberus-gaap:InvestorMember2024-07-310001877184ck0001877184:FirstTrancheMemberck0001877184:LenderMember2023-09-290001877184us-gaap:CommonStockMemberus-gaap:IPOMember2025-03-142025-03-140001877184us-gaap:MeasurementInputExpectedDividendRateMember2026-04-300001877184us-gaap:ConstructionInProgressMember2025-04-300001877184us-gaap:FairValueInputsLevel2Member2025-04-300001877184ck0001877184:FirstDrawMember2023-09-290001877184ck0001877184:FirstTrancheMemberck0001877184:LenderMembersrt:MaximumMember2023-09-290001877184ck0001877184:FourZeroOneKPlanMember2024-05-012025-04-300001877184us-gaap:CollateralizedCreditCardSecuritiesMember2026-04-300001877184us-gaap:MeasurementInputSharePriceMember2026-04-300001877184ck0001877184:MedicalRentalEquipmentMember2026-04-300001877184us-gaap:FairValueInputsLevel2Member2025-05-012026-04-300001877184ck0001877184:FirstDrawMember2023-09-292023-09-290001877184us-gaap:CommonStockMemberus-gaap:IPOMember2025-03-012025-03-310001877184ck0001877184:TermLoan2024Member2024-05-012025-04-300001877184us-gaap:RestrictedStockUnitsRSUMember2026-04-300001877184ck0001877184:MarketBasedRestrictedStockUnitsMember2026-04-300001877184country:IE2025-05-012026-04-300001877184us-gaap:CommonStockMemberus-gaap:IPOMember2026-04-30xbrli:purexbrli:sharesiso4217:USDxbrli:sharesck0001877184:Trancheck0001877184:Segmentiso4217:USD\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n \n\nFORM 10-K\n\n \n\n(Mark One)\n\n☒\n\nANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the fiscal year ended April 30, 2026\n\nOR\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nCommission File Number: 001-42549\n\n \n\nKestra Medical Technologies, Ltd.\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n \n\nBermuda\n\nNot Applicable\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\nIdentification No.)\n\n3933 Lake Washington Blvd NE, Suite 200\n\nKirkland, WA\n\n98033\n\n(Address of principal executive offices)\n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (425) 279-8002\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\n\nSymbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon Shares, par value $1.00 per share\n\n \n\nKMTS\n\n \n\nThe Nasdaq Stock Market LLC\n\nSecurities registered pursuant to Section 12(g) of the Act: None\n\nIndicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☒ No ☐\n\nIndicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒\n\nIndicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐\n\nIndicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\n \n\nEmerging growth company\n\n \n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\nIndicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒\n\nThe aggregate market value of the Registrant's Common Shares held by non-affiliates, based upon the closing price of the Common Shares on October 31, 2025, as reported by the Nasdaq Stock Market LLC, was approximately $618.7 million. Common Shares held by each executive officer and director and by each person who is deemed to be an affiliate of the Registrant have been excluded from such computation. This determination of affiliate status is not necessarily a conclusive determination for other purposes.\n\nThe number of shares of the Registrant’s Common Shares outstanding as of July 9, 2026 was 58,602,497.\n\nDOCUMENTS INCORPORATED BY REFERENCE\n\nThe information required by Part III of this Annual Report, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting to be held in 2026, which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates (the “Proxy Statement”).\n\n \n\n \n\n \n\n \n\nTable of Contents\n\n \n\nPage\n\nPART I"}